Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

De Backer, O, Pilgrim, T, Simonato, M, Mackensen, GB, Fiorina, C, Veulemanns, V, Cerillo, A, Schofer, J, Amabile, N, Achkouty, G, Schäfer, U, Deutsch, M-A, Sinning, J-M, Rahman, MS, Sawaya, FJ, Hildick-Smith, D, Hernandez, JM, Kim, W-K, Lefevre, T, Seiffert, M, Bleiziffer, S, Petronio, AS, Van Mieghem, N, Taramasso, M, Søndergaard, L, Windecker, S, Latib, A & Dvir, D 2018, 'Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation' The American journal of cardiology, bind 122, nr. 6, s. 1028-1035. https://doi.org/10.1016/j.amjcard.2018.05.044

APA

CBE

De Backer O, Pilgrim T, Simonato M, Mackensen GB, Fiorina C, Veulemanns V, Cerillo A, Schofer J, Amabile N, Achkouty G, Schäfer U, Deutsch M-A, Sinning J-M, Rahman MS, Sawaya FJ, Hildick-Smith D, Hernandez JM, Kim W-K, Lefevre T, Seiffert M, Bleiziffer S, Petronio AS, Van Mieghem N, Taramasso M, Søndergaard L, Windecker S, Latib A, Dvir D. 2018. Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. The American journal of cardiology. 122(6):1028-1035. https://doi.org/10.1016/j.amjcard.2018.05.044

MLA

Vancouver

Author

De Backer, Ole ; Pilgrim, Thomas ; Simonato, Matheus ; Mackensen, G Burkhard ; Fiorina, Claudia ; Veulemanns, Verena ; Cerillo, Alfredo ; Schofer, Joachim ; Amabile, Nicolas ; Achkouty, Guy ; Schäfer, Ulrich ; Deutsch, Marcus-André ; Sinning, Jan-Malte ; Rahman, Mohammed S ; Sawaya, Fadi J ; Hildick-Smith, David ; Hernandez, Jose Maria ; Kim, Won-Keun ; Lefevre, Thierry ; Seiffert, Moritz ; Bleiziffer, Sabine ; Petronio, Anna Sonia ; Van Mieghem, Nicolas ; Taramasso, Maurizio ; Søndergaard, Lars ; Windecker, Stephan ; Latib, Azeem ; Dvir, Danny. / Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation. I: The American journal of cardiology. 2018 ; Bind 122, Nr. 6. s. 1028-1035.

Bibtex

@article{0b851029c63543bea0991c5af48df486,
title = "Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation",
abstract = "Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the {"}off-label{"} use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2{\%}) underwent transcatheter aortic valve implantation (TAVI) with early generation (43{\%}) or newer generation (57{\%}) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82{\%} vs 47{\%}, p <0.001). The difference was driven by lower rates of device malpositioning (9{\%} vs 33{\%}) and aortic regurgitation (AR) ≥ moderate (4{\%} vs 31{\%}) and translated into higher clinical efficacy at 30 days in patients treated with newer as compared with early generation THV (72{\%} vs 56{\%}, p = 0.041). Both THV under- and oversizing were associated with an increased risk of THV malpositioning. In conclusion, TAVI is a feasible treatment strategy in selected high-risk patients with NAVR but is associated with a considerable risk of THV malpositioning and residual AR. Although newer-generation THV are associated with better outcomes, novel devices for the treatment of NAVR are warranted.",
author = "{De Backer}, Ole and Thomas Pilgrim and Matheus Simonato and Mackensen, {G Burkhard} and Claudia Fiorina and Verena Veulemanns and Alfredo Cerillo and Joachim Schofer and Nicolas Amabile and Guy Achkouty and Ulrich Sch{\"a}fer and Marcus-Andr{\'e} Deutsch and Jan-Malte Sinning and Rahman, {Mohammed S} and Sawaya, {Fadi J} and David Hildick-Smith and Hernandez, {Jose Maria} and Won-Keun Kim and Thierry Lefevre and Moritz Seiffert and Sabine Bleiziffer and Petronio, {Anna Sonia} and {Van Mieghem}, Nicolas and Maurizio Taramasso and Lars S{\o}ndergaard and Stephan Windecker and Azeem Latib and Danny Dvir",
note = "Copyright {\circledC} 2018. Published by Elsevier Inc.",
year = "2018",
month = "9",
day = "15",
doi = "10.1016/j.amjcard.2018.05.044",
language = "English",
volume = "122",
pages = "1028--1035",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Excerpta Medica, Inc",
number = "6",

}

RIS

TY - JOUR

T1 - Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

AU - De Backer, Ole

AU - Pilgrim, Thomas

AU - Simonato, Matheus

AU - Mackensen, G Burkhard

AU - Fiorina, Claudia

AU - Veulemanns, Verena

AU - Cerillo, Alfredo

AU - Schofer, Joachim

AU - Amabile, Nicolas

AU - Achkouty, Guy

AU - Schäfer, Ulrich

AU - Deutsch, Marcus-André

AU - Sinning, Jan-Malte

AU - Rahman, Mohammed S

AU - Sawaya, Fadi J

AU - Hildick-Smith, David

AU - Hernandez, Jose Maria

AU - Kim, Won-Keun

AU - Lefevre, Thierry

AU - Seiffert, Moritz

AU - Bleiziffer, Sabine

AU - Petronio, Anna Sonia

AU - Van Mieghem, Nicolas

AU - Taramasso, Maurizio

AU - Søndergaard, Lars

AU - Windecker, Stephan

AU - Latib, Azeem

AU - Dvir, Danny

N1 - Copyright © 2018. Published by Elsevier Inc.

PY - 2018/9/15

Y1 - 2018/9/15

N2 - Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the "off-label" use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2%) underwent transcatheter aortic valve implantation (TAVI) with early generation (43%) or newer generation (57%) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82% vs 47%, p <0.001). The difference was driven by lower rates of device malpositioning (9% vs 33%) and aortic regurgitation (AR) ≥ moderate (4% vs 31%) and translated into higher clinical efficacy at 30 days in patients treated with newer as compared with early generation THV (72% vs 56%, p = 0.041). Both THV under- and oversizing were associated with an increased risk of THV malpositioning. In conclusion, TAVI is a feasible treatment strategy in selected high-risk patients with NAVR but is associated with a considerable risk of THV malpositioning and residual AR. Although newer-generation THV are associated with better outcomes, novel devices for the treatment of NAVR are warranted.

AB - Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the "off-label" use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2%) underwent transcatheter aortic valve implantation (TAVI) with early generation (43%) or newer generation (57%) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82% vs 47%, p <0.001). The difference was driven by lower rates of device malpositioning (9% vs 33%) and aortic regurgitation (AR) ≥ moderate (4% vs 31%) and translated into higher clinical efficacy at 30 days in patients treated with newer as compared with early generation THV (72% vs 56%, p = 0.041). Both THV under- and oversizing were associated with an increased risk of THV malpositioning. In conclusion, TAVI is a feasible treatment strategy in selected high-risk patients with NAVR but is associated with a considerable risk of THV malpositioning and residual AR. Although newer-generation THV are associated with better outcomes, novel devices for the treatment of NAVR are warranted.

U2 - 10.1016/j.amjcard.2018.05.044

DO - 10.1016/j.amjcard.2018.05.044

M3 - Journal article

VL - 122

SP - 1028

EP - 1035

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -

ID: 56519824